达格列净片在冠心病合并2型糖尿病治疗中的应用与作用探究

Application and Effect of Dagglijing Tablets in the Treatment of Coronary Heart Disease Complicated with type 2 Diabetes Mellitus

目的探析达格列净片在冠心病合并2型糖尿病(T2DM)治疗中的应用与作用。方法选取本院冠心病三科内分泌科2018年7月至2020年7月收治的208例冠心病合并T2DM患者,随机分为两组,各104例。两组均给予常规对症冠心病合并T2DM治疗,观察组联合达格列净片,比较两组临床疗效、糖尿病ABC指标及安全指标情况。结果观察组(联合达格列净片)疗效率为98.08%,明显高于对照组(常规治疗)89.42%(P<0.05);观察组(联合达格列净片)总不良反应率(4.81%)明显低于对照组(常规治疗)不良反应率(12.50%),其中观察组的MACE发生率(0.96%)远低于对照组(6.73%)(P<0.05);观察组糖尿病ABC指标均明显优于对照组(P<0.05)。结论达格列净片治疗冠心病合并T2DM临床效果显著,可有效改善血糖、血压、血脂指标,降低心血管风险事件发生率,值得临床推广。

Objective To explore the application and effect of dagglijing tablets in the treatment of coronary heart disease complicated with type 2 diabetes mellitus(T2DM).Methods A total of 208 patients with coronary heart disease and T2DM who were admitted to the Endocrinology Department of the Third Department of Coronary Heart Disease in our hospital from July 2018 to July 2020 were selected and randomly divided into two groups with 104 cases in each group.The two groups were given conventional symptomatic coronary heart disease combined with T2DM treatment,and the observation group was combined with dagglijing tablets.The clinical efficacy,diabetes ABC index and safety index of the two groups were compared.Results The treatment efficiency of the observation group(combined with dagglijing tablets)was 98.08%,which was significantly higher than 89.42%of the control group(conventional treatment)(P<0.05).The total adverse reaction rate of the observation group(combined with dagglijing tablets)(4.81%)was significantly lower than that of the control group(12.50%).The incidence of mace in the observation group(0.96%)was much lower than that in the control group(6.73%)(P<0.05).The ABC indexes of diabetes in the observation group were significantly better than those in the control group(P<0.05).Conclusion The clinical effect of dagglijing tablets in the treatment of coronary heart disease complicated with T2DM is significant,which can effectively improve blood glucose,blood pressure,blood lipid indicators,and reduce the incidence of cardiovascular risk events,which is worthy of clinical promotion.